Breaking News

F1 Oncology Expands Operations

International affiliate, Exuma Biotechnology, acquires CAR-T assets

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

F1 Oncology, a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, said that its international affiliate, EXUMA Biotechnology, which is based in Hong Kong, has formed Shanghai EXUMA Biotechnology, a wholly foreign-owned enterprise, to acquire all rights to novel chimeric antigen receptor T (CAR-T) cell therapy and manufacturing assets in Shanghai and Shenzhen for the development and commercialization of cellular therapies in Greater China to be u...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters